復宏漢霖(02696.HK)漢斯狀注射液化療非小細胞肺癌新適應症NDA獲受理
復宏漢霖(02696.HK)公布,近日公司自主開發的漢斯狀(斯魯利單抗注射液)聯合培美曲塞和卡鉑適用於表皮生長因子受體(EGFR)敏感性突變陰性和間變性淋巴瘤激(酉每)(ALK)基因重排陰性的局部晚期或轉移性非鱗狀非小細胞肺癌(NSCLC)的一線治療新適應症的上市註冊申請(NDA)獲國家藥品監督管理局藥品審評中心受理,該適應症為漢斯狀於中國境內第五項申報上市的適應症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.